Grupo Fisiopatología Endocrina, Nutricional y Médica
FENM
Hospital Universitario La Fe
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (9)
2024
-
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-related cancer
-
Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466
-
Glucose metabolism outcomes after pituitary surgery in patients with acromegaly
Pituitary
-
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-Related Cancer, Vol. 31, Núm. 7
2023
-
Mortality in Acromegaly Diagnosed in Older Individuals in Spain Is Higher in Women Compared to the General Spanish Population
The Journal of clinical endocrinology and metabolism, Vol. 108, Núm. 9, pp. 2193-2202
2022
-
Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
Frontiers in Endocrinology, Vol. 13
-
RICORS2040: The need for collaborative research in chronic kidney disease
Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387
2019
-
Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study
Pituitary, Vol. 22, Núm. 2, pp. 137-145
2014
-
The Lin28/Let-7 system in early human embryonic tissue and ectopic pregnancy
PLoS ONE, Vol. 9, Núm. 1